Precision targeting in biliary tract cancer therapy: A geographical, target, and efficacy analysis of clinical trials.
BACKGROUND: Despite a significant increase in clinical trials for biliary tract cancers (BTCs) over the past decade, progress in precision therapy has been limited by insufficient understanding of treatment strategies and target specificity. CHEK1, ATR, DNMT1, AURKA, and CA9 represent potential targets demonstrating high safety and specificity.
BACKGROUND: Despite a significant increase in clinical trials for biliary tract cancers (BTCs) over the past decade, progress in precision therapy has been limited by insufficient understanding of treatment strategies and target specificity. CHEK1, ATR, DNMT1, AURKA, and CA9 represent potential targets demonstrating high safety and specificity.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochimica et biophysica acta. Reviews on cancer
Why it surfaced
Relevant Novel therapeutics: immunotherapy, CAR-T, targeted therapy study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.